Finanzen von Candel Therapeutics Inc (CADL)CADLCandel Therapeutics Inc

Evaluating the bottom line, Candel Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -81.84%, provide a clear picture of how effectively CADL converts its operational activities into shareholder value.

In the context of the broader market, CADL competes directly with industry leaders such as ATTO and PRME. With a market capitalization of $739.17M, it holds a leading position in the sector. When comparing efficiency, CADL's gross margin of N/A stands against ATTO's 100.00% and PRME's 100.00%. Such benchmarking helps identify whether Candel Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Candel Therapeutics has shown volatility in its earnings, with a net income of -38905000 USD in Q2 2026 and a forward P/E ratio of 43.4783, indicating high expectations for future earnings despite current losses.